Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03931174
Other study ID # #1811002260
Secondary ID R01DA046941
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 9, 2019
Est. completion date June 2024

Study information

Verified date February 2023
Source Brown University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There is an urgent need for effective treatments for patients with opioid use disorder (OUD). This study will train opioid treatment centers in an evidence-based behavioral treatment called contingency management (CM). Contingency management (i.e., motivational incentives for achieving pre-defined treatment goals) is one of the only behavioral interventions shown to improve patient treatment outcomes when combined with FDA-approved pharmacotherapy. Unfortunately, however, uptake of CM in OUD treatment centers remains low. In response to the urgent need for evidence-based behavioral OUD treatments, the investigators propose a large-scale type 3 hybrid trial comparing two comprehensive strategies to promote CM implementation as an adjunct to pharmacotherapy within OUD centers. The control condition is the staff training strategy used by the New England Addiction Technology Transfer Center, which consists of didactic workshop, performance feedback, and staff coaching. The experimental condition is the ATTC strategy enhanced by external leadership coaching (using a model called Implementation Sustainment Facilitation; ISF) and provider incentives (using a model called Pay for Performance; P4P). A cluster randomized design,trial will be conducted with 30 OUD treatment centers across New England. Centers will be randomized to one of the two implementation conditions (ATTC vs. enhanced-ATTC) over the 5 year project. At each OUD treatment center, data will be collected at multiple intervals from CM treatment providers, organizational leaders, and newly admitted patients. Additionally, patient charts will be randomly selected for review to examine sustainment. Data collection will include electronic medical record review, ratings of audio recordings by staff blind to condition, well-validated measures, and provider weekly report of patient encounter data. Specific Aims of the study are to experimentally compare the effect of the two conditions on implementation outcomes (Primary Aim) and on patient outcomes (Secondary Aim). An Exploratory Aim is to test whether two organization-level variables (i.e., implementation climate, leadership engagement) partially mediate the relationship between implementation condition and the key study outcomes.


Description:

Overdoses and deaths due to opioid use disorders (OUDs) have been declared a public health emergency in the United States, bringing to light an urgent need for highly effective OUD treatments. There are currently five FDA-approved medication formulations, which relative to placebo have demonstrated effectiveness in helping patients attain abstinence from opioids. Nonetheless, patients' opioid abstinence rates are sub-optimal: even when treated with the newest extended-release formulations only about 40% of patients maintain abstinence during the first 6-months of treatment. Contingency management (CM; i.e., motivational incentives for achieving pre-defined treatment goals) is one of the only behavioral interventions shown to improve patient abstinence from opioids when combined with FDA-approved pharmacotherapy. Unfortunately, however, uptake of CM in OUD treatment centers remains low. The primary purpose of this study is to experimentally evaluate two different comprehensive training models to train opioid treatment centers in CM. A Type 3 Hybrid Trial will be conducted collecting data on both implementation and patient outcomes. Using a cluster randomized design, 30 OUD treatment centers across New England will be randomized to one of two comprehensive training conditions over a 5 year period. The control condition is the staff training strategy used by the Substance Abuse and Mental Health Services Administration (SAMHSA)-funded network of Addiction Technology Transfer Centers (ATTC; i.e., didactic workshop + performance feedback + staff coaching). The experimental condition is the ATTC strategy enhanced by external leadership coaching (using a model called Implementation Sustainment Facilitation [ISF], i.e., leadership coaching focused on sustainment planning) and provider incentives (using a model called Pay for Performance [P4P]; i.e., monetary bonuses for achieving pre-defined implementation goals), hereafter referred to as E-ATTC. Elements of the E-ATTC condition were informed by our team's prior NIH-funded work evaluating organization-level implementation strategies. At each OUD treatment center, data will be collected at multiple intervals from 2-5 CM treatment providers (n=60-150 providers), 1-2 organizational leaders (n=30-60 leaders), and 25 newly admitted patients (n=750 patients). Additionally, 25 patient charts per center (n=750 charts) will be randomly selected for review to examine sustainment. Data collection will include electronic medical record review, ratings of audio recordings by staff blind to condition, well-validated measures, and biological verification of abstinence. The Primary Aim of the study is to experimentally compare the effect of the two training strategies on implementation outcomes. Focal implementation outcomes include: CM Exposure (patient-level measure of number of CM sessions received during 9-month Implementation phase) CM Competence (provider-level measure of CM quality during month Implementation phase), and CM Sustainment (patient-level measure of number of CM sessions received during 12-month Sustainment phase). The Secondary Aim of the study is to experimentally compare the effect of the two training strategies on patient outcomes. Focal patient outcomes include abstinence from opioids and opioid-related problems. An Exploratory Aim is to test whether two organization-level variables (i.e., implementation climate, leadership engagement) partially mediate the relationship between implementation condition and the key study outcomes. Pursuit of these aims is significant given the potential to improve the treatment of OUDs in community settings, which is one of the greatest public health challenges currently facing our nation. Major strengths of the approach include the study's experimental design (cluster randomized trial), novel implementation strategy based on mixed-methods pilot data by the investigative team, large sample of organizations (N = 30), partnership with a SAMHSA-funded national training center, and rigorously measured implementation and patient outcomes.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 960
Est. completion date June 2024
Est. primary completion date January 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria for community-based OUD treatment centers (n = 30): - prescribes FDA-approved medication to treat adult patients with OUDs - enrolls 5+ new patients per month - has at least 2 staff who provide psychosocial support to OUD patients Exclusion criteria: • None Inclusion criteria for CM Providers (n = 60-150, range of 2-5 per center): - has been involved in providing psychosocial support to OUD patients on pharmacotherapy - has an active caseload - is willing to commit to 14 months of CM training and support Exclusion criteria: • None Inclusion Criteria for CM Leaders (n = 30-60, range of 1-2 per center): - is responsible for supervising frontline CM Staff - is willing to commit to 14 months of external leadership coaching Exclusion criteria: • None Inclusion criteria for patients (n = 750): - adult patients - newly admitted to the opioid treatment center within the past 30 days - prescribed any FDA-approved OUD medication Exclusion criteria: • issues that could interfere with the ability to complete a brief intake interview including acute intoxication, acute psychosis, acute mania, or cognitive impairment (prohibiting comprehension of the consent process), as reported by opioid treatment center staff or observed by research staff

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Addiction Technology Transfer Center (ATTC) Training Strategy
Participating organizations will receive training consisting of 3 components: 1) didactic workshop - full-day workshop led by a contingency management (CM) expert for both CM staff and leaders, 2) performance feedback - submission of CM session recordings for review and performance feedback at least monthly for 9 months for CM staff, and 3) staff coaching - monthly provider coaching calls led by a CM expert for 9 months for both CM staff and leaders.
Enhanced Addiction Technology Transfer Center (E-ATTC) Training Strategy
Participating organizations will receive all of the elements of the ATTC control condition. In addition, organizations will receive two additional elements: 1) Implementation Sustainment Facilitation - monthly coaching calls for CM leaders and staff focused on sustainment, 2) Pay for Performance - participating CM staff will have the opportunity to earn monthly monetary bonuses for achieving pre-defined implementation goals for 9 months.

Locations

Country Name City State
United States BAART Programs Berlin Berlin Vermont
United States Kinsella Treatment Center Bridgeport Connecticut
United States Liberation Programs Bridgeport Bridgeport Connecticut
United States North Charles Institute for the Addictions Cambridge Massachusetts
United States CODAC Behavioral Healthcare - Eleanor Slater Cranston Rhode Island
United States Habit Opco East Wareham Comprehensive Treatment Center E. Wareham Massachusetts
United States Habit Opco Fall River Comprehensive Treatment Center Fall River Massachusetts
United States Spectrum Health Systems Framingham Framingham Massachusetts
United States Community Renewal Team Hartford Connecticut
United States Spectrum Health Systems Haverhill Haverhill Massachusetts
United States Spectrum Health Systems Leominster Leominster Massachusetts
United States Spectrum Health Systems Milford Milford Massachusetts
United States Spectrum Health Systems Millbury Millbury Massachusetts
United States Gifford Street Comprehensive Treatment Center New Bedford Massachusetts
United States Spectrum Health Systems North Adams North Adams Massachusetts
United States Spectrum Health Systems Pittsfield Pittsfield Massachusetts
United States CODAC Providence Providence Rhode Island
United States Discovery House Comprehensive Treatment Center Providence Rhode Island
United States Lifespan Recovery Center Providence Rhode Island
United States VICTA Providence Rhode Island
United States West Ridge Center Rutland Vermont
United States Spectrum Health Systems Southbridge Southbridge Massachusetts
United States Liberation Programs Stamford Stamford Connecticut
United States Habit Opco Taunton Comprehensive Treatment Center Taunton Massachusetts
United States Habit Opco West Lebanon Comprehensive Treatment Center W. Lebanon New Hampshire
United States Spectrum Health Systems Waltham Waltham Massachusetts
United States Spectrum Health Systems Weymouth Weymouth Massachusetts
United States Woonsocket Comprehensive Treatment Center Woonsocket Rhode Island
United States Spectrum Health Systems Worcester Worcester Massachusetts

Sponsors (5)

Lead Sponsor Collaborator
Brown University National Institute on Drug Abuse (NIDA), RTI International, UConn Health, University of Washington

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Implementation Climate Implementation climate scale (Jacobs et al., 2014). This scale contains 6 items scored on a 1 to 5 scale. An average score across the 6 items will be calculated per provider. Higher scores indicate a more positive implementation climate. Assessed at start of Preparation phase (provider baseline assessment) and start of Implementation phase (5-months post baseline)
Other Leadership Engagement Measure of leadership engagement (Garner, unpublished data). The scale contains 4 items scored on a 1 to 5 scale. An average perceived leadership engagement scale will be calculated for each provider. Higher scores indicate higher perceived leadership engagement. Assessed at start of Preparation phase (provider baseline assessment) and start of Implementation phase (5-months post baseline)
Primary CM exposure (implementation outcome) Proportion of target CM sessions received per recruited patient (25 patients per site X 30 sites = 750 patients) based on electronic medical record review and data entered into a study-specific CM tracker tool. Providers will report on patient encounters in the electronic medical record and the study-specific CM tracker tool, and for each encounter will report if CM was provided. Proportion of target CM sessions (target number = 12 over a 14 week period) will be calculated per patient. Calculated throughout the 9-month Implementation phase
Primary CM Competence (implementation outcome) Provider scores on the Contingency Management Competence Scale for Reinforcing Attendance (CMCS; Petry & Ledgerwood, 2010). Raters blind to treatment condition will code audio recorded CM sessions and rate them using the CMCS, which measures provider skill in CM delivery. CMCS contains 6 CM-specific skill items and 3 general practice skill items that are scored on a scale from 1 to 7, with higher scores indicating higher levels of provider skill. An average score across the 6 CM-specific skill items will be calculated for each provider. Providers will submit one audio recording per month for the duration of the 9-month Implementation phase. Assessed monthly throughout the 9-month Implementation phase
Primary CM Sustainment (implementation outcome) Proportion of target CM sessions received per patient based on electronic medical record review of 25 randomly selected charts per site (25 charts * 30 sites = 750 charts). Providers will report on patient encounters in the electronic medical record, and for each encounter will report if CM was provided. Proportion of target CM sessions (target number = 12 over a 14 week period) will be calculated per patient record. Assessed at the end of the 12-month Sustainment phase
Secondary Opioid Abstinence: Past Month (patient outcome) Days of abstinence as reported using calendar-based recall based on theTimeline Followback Interview method (Sobell & Sobell, 1992). Days of opioid abstinence will be calculated from 0 to 30 for each patient, with higher numbers indicating more days of abstinence.This will be calculated for all patients who complete follow-up. Assessed at 3 and 6-months from patient baseline assessment
Secondary Opioid-Related Problems: Past Month (patient outcome) Count of problems as reported using an adapted version of the Global Appraisal of Needs Substance Problems Scale (Dennis et al., 2002), which has been adapted to focus specifically on problems related to opioids. The scale contains 16 items that correspond to problems related to opioid use. Patients are asked the last time they received each problem with responses including past month, past year, lifetime, or never. A count of problems experienced over the past month will be calculated for each patient (possible range from 0 to 16), with higher scores indicating higher problems. This will be calculated for all patients who complete follow-up. Assessed at 3 and 6-months from patient baseline assessment
See also
  Status Clinical Trial Phase
Recruiting NCT04157062 - An Open-Label Trial of Repetitive Transcranial Magnetic Stimulation for Opioid Use Disorder N/A
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Completed NCT04505540 - Start Treatment and Recovery for Opioid Use Disorder N/A
Completed NCT03065049 - Transforming Recovery Through Exercise and Community N/A
Completed NCT04080037 - Assessing Opioid Care Practices Using CPV Patient Simulation Modules N/A
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Suspended NCT05001789 - Cognitive Functioning in Opioid Use Disorder N/A
Active, not recruiting NCT04650386 - Examining an Adaptive Approach to Providing Psychosocial Support to Buprenorphine Patients N/A
Completed NCT03715634 - Study of a Novel Subcutaneous Depot Formulation of Buprenorphine Phase 1
Enrolling by invitation NCT04991974 - Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine Phase 2/Phase 3
Completed NCT04122755 - Single Ascending Dose Study of ALA-1000 Phase 1
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Recruiting NCT05049460 - Adjunctive Transcranial Stimulation to Reduce Impulsivity in Opiate Use Disorder N/A
Recruiting NCT05028998 - COVID-19-Related Opioid Treatment Policy Evaluation
Completed NCT05047627 - Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder N/A
Active, not recruiting NCT04129580 - reSET-O RCT (Randomized Controlled Trial) N/A
Recruiting NCT03923374 - Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
Completed NCT04464421 - SMART Effectiveness Trial N/A
Completed NCT04056182 - Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment Phase 2
Suspended NCT02687360 - Imaging the Effects of rTMS on Chronic Pain N/A